Monocyclic β-lactam compounds for resistant Gram-negative bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial infections, particularly those caused by Gram-negative bacteria, are limited due to the rise of drug-resistant strains, with existing β-lactam antibiotics facing challenges from increasing resistance mechanisms such as extended spectrum lactamases and carbapenemases, necessitating the development of new compounds that can overcome bacterial resistance.
Innovation Solution
Development of specific monocyclic β-lactam compounds, represented by formulas (I′) and (II′), or their isomers and pharmaceutically acceptable salts, which exhibit enhanced antibacterial activity against Gram-negative bacteria, including resistant strains like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella, by modifying the structural substituents and incorporating specific heteroaryl and heterocycloalkyl groups.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing β-lactam antibiotics are used to treat Gram-negative bacterial infections, then treatment options are available, but bacterial resistance mechanisms (extended spectrum lactamases and carbapenemases) reduce effectiveness
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of monocyclic β-lactam compounds. Specifically, it varies substituents at different positions (R1 at N1-position, R2 at C3-position, R3 and R4 at C4-position) including heteroaryl groups, heterocycloalkyl groups, and their combinations, to optimize antibacterial activity against resistant Gram-negative bacteria while maintaining stability against β-lactamases
Solution Approach 2:
The patent employs composite material principles by creating complex molecular structures that combine multiple functional groups within the β-lactam core. The compounds integrate heteroaryl groups (such as pyridyl, pyrimidinyl), heterocycloalkyl groups (such as piperidinyl, morpholinyl), and various substituent patterns to achieve both permeability enhancement and resistance to bacterial degradation mechanisms
2Reliability
If monocyclic β-lactam compounds are developed with enhanced activity, then antibacterial spectrum is improved, but structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional regions: the core monocyclic β-lactam structure, N1-position substituents (R1), C3-position substituents (R2), and C4-position substituents (R3 and R4). This modular approach allows systematic optimization of each region's contribution to antibacterial activity while maintaining overall structural coherence
Solution Approach 2:
The patent implements local quality by assigning specific functional characteristics to different parts of the molecule. For example, heteroaryl groups at R1 enhance permeability, specific heterocycloalkyl groups at R2 improve stability, and particular substituent combinations at R3/R4 optimize binding affinity. Each local region is tailored to perform its specific function while contributing to overall efficacy
Data Source
AI summary
Disclosed are a class of new monocyclic β-lactam compounds, an isomer thereof or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compounds, and the use of same in preparing drugs for treating diseases associated with bacterial infection. Specifically disclosed are the compounds as shown in formula (I′) and formula (II′), isomers thereof or pharmaceutically acceptable salts thereof.